There is a thriving online market selling vials labeled "retatrutide", "reta", "GLP-3" or "GLP-3 RT" — usually stamped "research use only" or "not for human consumption." This page is about what that market actually is.
The short version: no legitimate retatrutide is for sale anywhere, at any price. Lilly states the drug is available only to clinical-trial participants [5] (plus, since August 2026, its physician-requested expanded access program [6]). Everything else — whatever the label says — is an unapproved product from an unregulated source.
What "research use only" really means
"RUO" labeling exists for laboratory reagents sold to research institutions. Sellers of weight-loss peptides borrow the label as legal cover while marketing to consumers with dosing-adjacent content and weight-loss testimonials. The FDA's position is blunt: retatrutide cannot be used in compounding under federal law, and unapproved GLP-1 products marketed for weight loss are a safety concern it is actively acting on. [1]
The enforcement record
| Date | Action |
|---|---|
| Sept 9, 2025 | FDA warning letter to GLP-1 Solution [2] |
| Mar 31, 2026 | FDA warning letter to Gram Peptides, which sold the drug as "GLP-1-R peptide" [3] |
| March 2026 | FDA warning letters to Prime Sciences ("GLP1-R") and Mile High Compounds (which published a "GLP-3 RT" dosing cheat sheet) [1] |
| Aug 24, 2026 (posted Sept 1) | FDA warning letters to five more sellers [1] |
| Aug 12, 2026 | Lilly sues six U.S. defendants — a med spa, a compounding pharmacy and peptide sellers. Lilly says it has flagged 200+ entities to the FDA and reported 14,000+ listings [4] |
Note the code names in that table. When sellers rename a drug to dodge enforcement, that is not a detail — it's the business model. (Seller names above are listed as plain text from public FDA records; we don't link to sellers.)
What's actually in the vial
Nobody outside the seller knows, and often not even them. The specific risks:
- Identity — whether the compound is retatrutide at all.
- Dose — the real Phase 3 program uses careful dose escalation; a mislabeled vial can deliver several times an intended dose.
- Purity — synthesis byproducts and contaminants that pharmaceutical manufacturing is designed to exclude.
- Sterility — these are injected products; a non-sterile vial is a direct infection risk.
- No medical supervision — trial participants get labs, monitoring and an exit plan. Buyers get an email receipt.
Every safety statistic in our side-effects article describes the real, monitored drug. None of it transfers to gray-market vials.
If you or someone you know is considering it
The legitimate paths exist and cost nothing to explore: clinical trials, Lilly's expanded access program, or — the practical answer for most people — an FDA-approved GLP-1 medication (semaglutide, tirzepatide) prescribed today by a licensed clinician. Find a weight-loss provider near you, and if a clinic you visit offers "reta now," that's a red flag worth walking away from — and reporting.